Semi-Annual Statement Of Cash Flows

BrightPath Biotherapeutics Co., Ltd. - Filing #7331490

Concept As at
2024-03-31
2023-04-01 to
2024-03-31
As at
2023-03-31
2022-04-01 to
2023-03-31
As at
2022-03-31
Semi-annual statement of cash flows
Statement of cash flows
Cash flows from operating activities
Profit (loss) before income taxes
-1,166,182,000 JPY
-1,483,733,000 JPY
Depreciation
395,000 JPY
16,719,000 JPY
Impairment losses
7,252,000 JPY
9,958,000 JPY
Interest and dividend income
-12,000 JPY
-20,000 JPY
Increase (decrease) in provision for retirement benefits
2,821,000 JPY
2,183,000 JPY
Decrease (increase) in trade receivables
49,000 JPY
16,530,000 JPY
Increase (decrease) in trade payables
-56,000 JPY
-1,835,000 JPY
Other, net
698,000 JPY
238,335,000 JPY
Subtotal
-1,155,034,000 JPY
-1,201,800,000 JPY
Interest and dividends received
13,000 JPY
21,000 JPY
Interest paid
JPY
-202,000 JPY
Income taxes paid
-1,900,000 JPY
-2,420,000 JPY
Net cash provided by (used in) operating activities
-1,156,920,000 JPY
-1,204,401,000 JPY
Cash flows from investing activities
Purchase of property, plant and equipment
-6,194,000 JPY
-1,005,000 JPY
Net cash provided by (used in) investing activities
-7,648,000 JPY
-1,760,000 JPY
Cash flows from financing activities
Proceeds from issuance of bonds
500,000,000 JPY
JPY
Redemption of bonds
-387,500,000 JPY
-87,500,000 JPY
Purchase of treasury shares
JPY
0 JPY
Net cash provided by (used in) financing activities
690,959,000 JPY
432,104,000 JPY
Net increase (decrease) in cash and cash equivalents
-473,609,000 JPY
-774,056,000 JPY
Cash and cash equivalents
1,057,360,000 JPY
1,530,969,000 JPY
2,305,026,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.